Stem cell treatment for Crohn’s disease

References

• Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn’s disease. Nat. Rev. Gastroenterol. Hepatol.7(1), 79–85 (2010).
   PubMed Web of Science ®Google Scholar
• Salas A, Ricart E, Panes J. Cell therapies for inflammatory bowel diseases, Expert Rev. Gastroenterol. Hepatol.3(4), 321–324 (2009).
   PubMedGoogle Scholar
• Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells25(11), 2739–2749 (2007).
   PubMed Web of Science ®Google Scholar
• Dominici M, Le BK, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy8(4), 315–317 (2006).
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Passweg J, Bocelli-Tyndall C et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant.35(9), 869–879 (2005).
   PubMed Web of Science ®Google Scholar
• Kapoor S, Wilson AG, Sharrack B et al. Haemopoietic stem cell transplantation – an evolving treatment for severe autoimmune and inflammatory diseases in rheumatology, neurology and gastroenterology. Hematology12(3), 179–191 (2007).
   PubMed Web of Science ®Google Scholar
• Marmont AM. Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases. New perspectives, new problems. Haematologica86(4), 337–345 (2001).
   PubMed Web of Science ®Google Scholar
• Nash RA, McSweeney PA, Crofford LJ et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood110(4), 1388–1396 (2007).
   PubMed Web of Science ®Google Scholar
• Burt RK, Marmont A, Oyama Y et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum.54(12), 3750–3760 (2006).
   PubMed Web of Science ®Google Scholar
• Burt RK, Traynor A, Statkute L et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA295(5), 527–535 (2006).
   PubMed Web of Science ®Google Scholar
• Jayne D, Passweg J, Marmont A et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus13(3), 168–176 (2004).
   PubMed Web of Science ®Google Scholar
• Farge D, Labopin M, Tyndall A et al. Autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases: an observational study on 12 years of experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. Haematologica95(2), 284–292 (2010).
   PubMed Web of Science ®Google Scholar
• Burt RK, Loh Y, Cohen B et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a Phase I/II study. Lancet Neurol.8(3), 244–253 (2009).
   PubMed Web of Science ®Google Scholar
• Veny M, Esteller M, Ricart E, Pique JM, Panes J, Salas A. Late Crohn’s disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment. Pharmacol. Ther.31(5), 561–572 (2009).
   PubMedGoogle Scholar
• Drakos PE, Nagler A, Or R. Case of Crohn’s disease in bone marrow TransplantationAm. J. Hematol.43(2), 157–158 (1993).
   PubMed Web of Science ®Google Scholar
• Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn’s disease after allogeneic marrow transplantation. Gastroenterology114(3), 433–440 (1998).
   PubMed Web of Science ®Google Scholar
• Ditschkowski M, Einsele H, Schwerdtfeger R et al. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation75(10), 1745–1747 (2003).
   PubMed Web of Science ®Google Scholar
• Talbot DC, Montes A, Teh WL, Nandi A, Powles RL. Remission of Crohn’s disease following allogeneic bone marrow transplant for acute leukaemia. Hosp. Med.59(7), 580–581 (1998).
   PubMedGoogle Scholar
• Castro J, Bentch H, Smith LC et al. Prolonged clinical remission in patients with inflammatory bowel disease (IBD) after high dose chemotherapy (HDC) and autologous blood stem cell transplantation. Blood88(Suppl.), 133A (1996).
   Web of Science ®Google Scholar
• Kashyap A, Forman SJ. Autologous bone marrow transplantation for non-Hodgkin’s lymphoma resulting in long-term remission of coincidental Crohn’s disease. Br. J. Haematol.103(3), 651–652 (1998).
   PubMed Web of Science ®Google Scholar
• Musso M, Porretto F, Crescimanno A, Bondi F, Polizzi V, Scalone R. Crohn’s disease complicated by relapsed extranodal Hodgkin’s lymphoma: prolonged complete remission after unmanipulated PBPC autotransplant. Bone Marrow Transplant.26(8), 921–923 (2000).
   PubMed Web of Science ®Google Scholar
• Soderholm JD, Malm C, Juliusson G, Sjodahl R. Long-term endoscopic remission of Crohn disease after autologous stem cell transplantation for acute myeloid leukaemia. Scand. J. Gastroenterol.37(5), 613–616 (2002).
   PubMed Web of Science ®Google Scholar
• Anumakonda V, Hayee B, Chung-Faye G. Remission and relapse of Crohn’s disease following autologous haematopoietic stem cell transplantation for non-Hodgkin’s lymphoma. Gut56(9), 1325 (2007).
   PubMed Web of Science ®Google Scholar
• Marti JL, Mayordomo JI, Isla MD, Saenz A, Escudero P, Tres A. PBSC autotransplant for inflammatory bowel disease (IBD): a case of ulcerative colitis. Bone Marrow Transplant.28(1), 109–110 (2001).
   PubMedGoogle Scholar
• Sonwalkar SA, James RM, Ahmad T et al. Fulminant Crohn’s colitis after allogeneic stem cell transplantation. Gut52(10), 1518–1521 (2003).
   PubMed Web of Science ®Google Scholar
• Craig RM, Traynor A, Oyama Y, Burt RK. Hematopoietic stem cell transplantation for severe Crohn’s disease. Bone Marrow Transplant.32(Suppl. 1), S57–S59 (2003).
   Web of Science ®Google Scholar
• Oyama Y, Craig RM, Traynor AE et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology128(3), 552–563 (2005).
   PubMed Web of Science ®Google Scholar
• Cassinotti A, Annaloro C, Ardizzone S et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease. Gut57(2), 211–217 (2008).
   PubMed Web of Science ®Google Scholar
• Scime R, Cavallaro AM, Tringali S et al. Complete clinical remission after high-dose immune suppression and autologous hematopoietic stem cell transplantation in severe Crohn’s disease refractory to immunosuppressive and immunomodulator therapy. Inflamm. Bowel. Dis.10(6), 892–894 (2004)
   PubMed Web of Science ®Google Scholar
• Kreisel W, Potthoff K, Bertz H et al. Complete remission of Crohn‘s disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant.32(3), 337–340 (2003).
   PubMed Web of Science ®Google Scholar
• Glocker EO, Kotlarz D, Boztug K et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med.19, 361(21), 2033–2045 (2009).
   Google Scholar
• Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol.8(9), 726–736 (2008).
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science284(5411), 143–147 (1999).
   PubMed Web of Science ®Google Scholar
• Dazzi F, van Laar JM, Cope A, Tyndall A. Cell therapy for autoimmune diseases. Arthritis Res. Ther.9(2), 206 (2007).
   PubMed Web of Science ®Google Scholar
• Panes J, Salas A. Mechanisms underlying the beneficial effects of stem cell therapies for inflammatory bowel diseases. Gut58(7), 898–900 (2009).
   PubMedGoogle Scholar
• Gonzalez-Rey E, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut58(7), 929–939 (2009).
   PubMed Web of Science ®Google Scholar
• Fang B, Song YP, Liao LM, Han Q, Zhao RC. Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant.38(5), 389–390 (2006).
   PubMed Web of Science ®Google Scholar
• Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol.30(1), 42–48 (2002).
   PubMed Web of Science ®Google Scholar
• Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc. Natl Acad. Sci. USA100(14), 8407–8411 (2003).
   PubMed Web of Science ®Google Scholar
• Fang B, Shi M, Liao L, Yang S, Liu Y, Zhao RC. Systemic infusion of FLK1+ mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation78(1), 83–88 (2004).
   PubMed Web of Science ®Google Scholar
• Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am. J. Physiol. Renal Physiol.292(5), F1626–F1635 (2007).
   PubMed Web of Science ®Google Scholar
• Zappia E, Casazza S, Pedemonte E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood106(5), 1755–1761 (2005).
   PubMed Web of Science ®Google Scholar
• Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology136(3), 978–989 (2009).
   PubMed Web of Science ®Google Scholar
• Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant.30(4), 215–222 (2002).
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc. Natl Acad. Sci. USA99(13), 8932–8937 (2002).
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a Phase II study. Lancet371(9624), 1579–1586 (2008).
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet363(9419), 1439–1441 (2004).
   PubMed Web of Science ®Google Scholar
• Larghero J, Farge D, Braccini A et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann. Rheum. Dis.67(4), 443–449 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A Phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis. Colon Rectum48(7), 1416–1423 (2005).
   PubMed Web of Science ®Google Scholar